Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

FTSE 250 movers: TBC takes off; Ocado slips again

(Sharecast News) - FTSE 250 (MCX) 20,911.62 -0.04%

TBC Bank impressed on Wednesday by reporting record revenues and a big jump in profits in the fourth quarter, with the UK-listed Georgian bank confident of hitting its strategic targets for 2025.

Total operating income was up 22.6% year-on-year at an all-time high of 784m Georgian lari (£226m) in the final three months of 2024, with net interest income rising 14.9% to GEL508m, net fee and commission income up 34.4% at GEL148m, and other non-interest income was 46.4% higher at GEL128m.

Results were driven by the payments business in Georgia and strong growth in Uzbekistan, where TBC scaled up during the year with total users rising 37% to 18m and its loan book more than doubling.

Adjusted net profits for the fourth quarter were up 18.2% at GEL344m.

For 2024 as a whole, total operating income was 19.4% higher at GEL2.83bn, while adjusted net profit rose 15.6% to a record GEL1.32bn.

TBC declared a final dividend of GEL5.55, taking the full-year payout to GEL8.10, up 12% on 2023.

"As a team, we achieved a great deal in 2024, but as always there remains much to do, and we look forward to 2025 being another year of further scaling up our business in Uzbekistan and continuing to deliver strong and profitable growth in Georgia. I am confident we are fully on track to meet the mid-term targets we have set for 2025," said chief executive Vakhtang Butskhrikidze.

Indivior announced a delay in the US Food and Drug Administration's (FDA) final review of proposed label changes for its 'Sublocade', or buprenorphine extended-release, injection on Wednesday.

The company was expecting a decision by 7 February, as per the Prescription Drug User Fee Act (PDUFA) timeline.

It said on Wednesday that the FDA informed the company on 11 February that there were no outstanding issues following acceptance of the proposed label, which includes a rapid initiation protocol and alternative injection sites.

However, the final review process has been delayed.

The company did not provide a revised timeline for approval but said it would issue further updates as appropriate.

Ocado shares fell again, down 5%.

Market Movers

FTSE 250 - Risers

TBC Bank Group (TBCG) 4,100.00p 10.96% Lion Finance Group (BGEO) 5,320.00p 6.83% Indivior (INDV) 804.50p 5.16% Baltic Classifieds Group (BCG) 360.00p 4.50% Bluefield Solar Income Fund Limited (BSIF) 85.20p 3.78% Ithaca Energy (ITH) 135.70p 3.43% Foresight Solar Fund Limited (FSFL) 78.20p 3.17% Moonpig Group (MOON) 222.50p 2.30% W.A.G Payment Solutions (WPS) 68.80p 2.08% Genus (GNS) 1,842.00p 1.88%

FTSE 250 - Fallers

Ocado Group (OCDO) 310.90p -5.07% Raspberry PI Holdings (RPI) 688.25p -3.81% Travis Perkins (TPK) 682.50p -2.99% OSB Group (OSB) 413.00p -2.46% Endeavour Mining (EDV) 1,722.00p -2.44% Spectris (SXS) 2,998.00p -2.28% Zigup (ZIG) 306.00p -1.92% Oxford Instruments (OXIG) 1,942.00p -1.92% Drax Group (DRX) 644.50p -1.90% GCP Infrastructure Investments Ltd (GCP) 76.00p -1.81%

Share this article

Related Sharecast Articles

FTSE 100 movers: Defensives gain, cyclicals tumble as stocks in freefall
(Sharecast News) - London's FTSE 100 was down a whopping 4.4% at 8,105.43 in afternoon trade on Friday, with markets in freefall after China announced retaliatory tariffs on the US.
FTSE 250 movers: Currys surges; Vietnam funds battered
(Sharecast News) - FTSE 250 (MCX) 19,339.18 -1.58%
FTSE 100 movers: Banks in the red; utilities gain
(Sharecast News) - London's FTSE 100 was down 1.3% at 8,494.83 in afternoon trade on Thursday as investors mulled Trump's bombshell tariff announcement.
FTSE 100 movers: Rolls-Royce, GSK pace losses
(Sharecast News) - Rolls-Royce, GSK and Melrose Industries were among the worst performers.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.